Exact Sciences (EXAS)
(Delayed Data from NSDQ)
$56.36 USD
-2.46 (-4.18%)
Updated Aug 14, 2024 03:59 PM ET
After-Market: $56.56 +0.20 (0.35%) 7:58 PM ET
2-Buy of 5 2
D Value A Growth F Momentum B VGM
Brokerage Reports
Exact Sciences Corporation [EXAS]
Reports for Purchase
Showing records 241 - 260 ( 369 total )
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
Optimistic Post Meetings with CEO - FDA Progress Continues - Testing Interval on Investors'' Minds - Reimbursement & Commercial Story Ok - Reaffirm OP
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
3Q13 Recap - Bullish Reimbursement Tone - Journal Acceptance Positive, but Publication Now 1Q14 - Tweaking Rev Model by a Qtr. to Be Safe - Reaffirm OP
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
Slight Delay in FDA Panel, DeeP-C Publication but Overall On Track
Provider: Roth Capital Partners, Inc.
Analyst: LEWIS C
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
3Q13 Preview - Expecting Solid Overall Tone and Better Clarity on Gov''t Shutdown, Commercial Build-out and FDA Calendar - Reaffirming OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
Upgrading to OUTPERFORM from NEUTRAL - Sentiment and Competitive Confusion Sets Up Attractive Opportunity in Front of Multiple Catalysts
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
Healthcare - 3Q 2013: Quarterly Medical Technology Trading & Acquisition Update
Provider: Roth Capital Partners, Inc.
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
Morning Call
Provider: The Benchmark Company
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
Assuming Coverage with a Speculative Buy Rating
Provider: The Benchmark Company
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
2Q13 Recap - FDA & CMS Dialogue On Track - Raising Estimates on Higher Reimbursement and Accrual Accounting Assumptions - PT to $12
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
2Q Preview: Looking for PMA / NCD Updates, Commercialization Detail
Provider: Roth Capital Partners, Inc.
Analyst: LEWIS C